US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 5.82 against a street estimate of 6.86 — a miss of 15.2%.
Analysts rate United Therapeutics Corporation a buy (12 buy, 3 hold, 0 sell out of 15) with an average price target of $663.23.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.72% |
| venBio Select Advisor LLC | 6.20% |
| Wellington Management Company LLP | 5.33% |
| Vanguard Portfolio Management, LLC | 4.72% |
| Vanguard Capital Management, LLC | 4.61% |
| State Street Corp | 4.34% |
| Renaissance Technologies Corp | 4.21% |
| Geode Capital Management, LLC | 2.90% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-23 |
| Board / officer change · Q2 2026 | 2026-06-29 |
| Results announced · Q2 2026 | 2026-05-06 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Company announcement · Q1 2026 | 2026-03-30 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-10-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board approves $2.0 billion share repurchase program and enters ASR agreements United Therapeutics Corporation announced a $2.0 billion share repurchase program approved by its Board on March 8, 2026. The company immediately committed $1.5 billion through two accelerat | 2026-03-09 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for United Therapeutics Corporation — free to start.
Google PlayApp StoreData updated 2026-08-05.